"[There is] a lot of
intrigue as well as a lot of interest in understanding whether or not this
'integration' between a health plan and a PBM has financial and qualitative or clinical
value."
— Nadina
Rosier, Pharm.D., health and group benefits practice leader, pharmacy at Willis
Towers Watson, spoke with AIS's RADAR
on Drug Benefits about increasing integration between medical and
drug benefits, and how employer groups are rethinking their 2020 contracts.
No comments:
Post a Comment